Document is current
Any future updates will be listed below
-
Authors
Zaigham, Suneela
Gonçalves, Isabel
Center, Regeneron Genetics
Engström, Gunnar
Sun, Jiangming
-
Funding
Funding for this research was provided by:
Magnus Bergvalls Stiftelse (2021-04187)
Hjärt-Lungfonden (2020-0173)
Lund University
- License Information
-
More Information
Article History
Received: 25 July 2022
Accepted: 7 October 2022
First Online: 3 November 2022
Declarations
:
: For MDCS, all participants provided written consent, and the Ethical Committee at Lund University, Lund, Sweden approved the study (LU 51–90, LU 2009/633, LU 2011/356). For MPP, written consent was not available between 1974 and 1992, however verbal consent was taken for all participants included in the study. The Regional Ethics Committee at Lund (LU 85–2004; LU 2011–412) approved prospective follow-up of the cohort and data linkage with the national Cause of Death and Patient Registers.
: Not applicable.
: SZ, IG, GE and JS have no conflicts of interest to declare. The Regeneron Genetics Center is a subsidiary of Regeneron Pharmaceuticals, Inc.
